|
|
||||||||
BASIC SCIENCE INVESTIGATIONS |
Departments of Radiology and Surgery and UCSD Cancer Center, University of California, San Diego, La Jolla, California
We report the synthesis and preliminary biologic testing of a synthetic macromolecule, 99mTc-diethylenetriaminepentaacetic acid (DTPA)mannosyl-dextran, for sentinel node detection. Methods: Synthesis started with a 2-step process that attaches a high density of amino-terminated leashes to a dextran backbone. Allyl-bromide was reacted with pharmaceutical-grade dextran to yield allyl-dextran. After diafiltration with water, filtration, and lyophilization, the product was reacted with aminoethanethiol and ammonium persulfate. The resulting amino-conjugated dextran was dialyzed, filtered, and lyophilized. The mixed anhydride method was used to attach DTPA; after dialysis, filtration, and lyophilization, 2-imino-2-methoxyethyl-1-D-mannose was used to attach the receptor substrate. The molecular diameter was measured by dynamic light scattering. Amino, mannose, and DTPA densities were measured by trinitrobenzene sulfonate assay, sulfuric acid/phenol assay, and inductively coupled plasma spectroscopy of gadolinium-DTPA-mannosyl-dextran, respectively. Receptor affinity was measured by Scatchard assay of rabbit liver. Axillary, popliteal, and iliac lymph nodes and each injection site were assayed for radioactivity at 1 and 3 h after injection of approximately 3.7 MBq (0.050 mL) 99mTc-DTPA-mannosyl-dextran (0.22 nmol) or filtered 99mTc-sulfur colloid into the foot pads. Four animals were studied at each time point. Results: DTPA-mannosyl-dextran had a molecular weight of 35,800 g/mol and a molecular diameter of 7.1 nm. The final amine, mannose, and DTPA densities were 23, 55, and 8 mol per dextran. Labeling yields were in excess of 98% and stable for 6 h. Specific activities of 74 x 106 GBq/mol were achieved. The equilibrium dissociation constant for binding to the mannose-terminated glycoprotein receptor was 0.12 ± 0.07 nmol/L. The popliteal extraction at both 1 h and 3 h was significantly (P < 0.05) higher for 99mTc-DTPA-mannosyl-dextran (90.1% ± 10.7% and 97.7% ± 2.0%, respectively) than for filtered 99mTc-sulfur colloid (78.8 ± 6.5 and 67.4% ± 26.8%, respectively). 99mTc-DTPA-mannosyl-dextran exhibited significantly faster injection site clearance than did filtered 99mTc-sulfur colloid. The 99mTc-DTPA-mannosyl-dextran percentage injected dose (%ID) for the front and rear paws was 52.6 ± 10.5 and 52.3 ± 8.0 at 1 h and 45.7 ± 8.5 and 43.6 ± 8.2 at 3 h after administration. The filtered 99mTc-sulfur colloid %ID for the front and rear paws was 70.4 ± 11.0 and 66.3 ± 15.1 at 1 h and 55.5 ± 7.8 and 66.9 ± 8.5 at 3 h. Lymph node accumulation of each agent at either 1 or 3 h was not significantly different. Conclusion: 99mTc-DTPA-mannosyl-dextran is a receptor-based sentinel node radiotracer that exhibits the desired properties of rapid injection site clearance and low distal node accumulation. This molecule is the first member of a new class of diagnostic agents based on a macromolecular backbone with a high density of sites for the attachment of substrates and imaging reporters.
Key Words: sentinel node 99mTc DTPA-mannosyl-dextran receptor-binding radiopharmaceutical
This article has been cited by other articles:
![]() |
A. M. Wallace, C. K. Hoh, S. J. Ellner, D. D. Darrah, G. Schulteis, and D. R. Vera Lymphoseek: A Molecular Imaging Agent for Melanoma Sentinel Lymph Node Mapping Ann. Surg. Oncol., February 1, 2007; 14(2): 913 - 921. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Ellner, J. Mendez, D. R. Vera, C. K. Hoh, W. L. Ashburn, and A. M. Wallace Sentinel Lymph Node Mapping of the Colon and Stomach Using Lymphoseek in a Pig Model Ann. Surg. Oncol., July 1, 2004; 11(7): 674 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mendez, A. M. Wallace, C. K. Hoh, and D. R. Vera Detection of Gastric and Colonic Sentinel Nodes Through Endoscopic Administration of 99mTc-DTPA-Mannosyl-Dextran in Pigs J. Nucl. Med., October 1, 2003; 44(10): 1677 - 1681. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Wallace, C. K. Hoh, D. R. Vera, D. D. Darrah, and G. Schulteis Lymphoseek: A Molecular Radiopharmaceutical for Sentinel Node Detection Ann. Surg. Oncol., June 1, 2003; 10(5): 531 - 538. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koizumi, M. Makita, M. Yoshimoto, F. Kasumi, G. Sakamoto, and E. Ogata Indications for Sentinel Lymph Node Biopsy in Patients with Breast Cancer: Retrospective and Simulation Analyses Jpn. J. Clin. Oncol., December 1, 2002; 32(12): 517 - 524. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |